Gilead woos filgotinib clinical investigator from Stanford to lead the charge on NASH, inflammatory diseases
With an FDA OK for the use of filgotinib in rheumatoid arthritis expected to drop weeks from now, Gilead has recruited a new leader from academia to lead its foray into inflammatory diseases.
Mark Genovese — a longtime Stanford professor and most recently the clinical chief in the division of immunology and rheumatology — was the principal investigator in FINCH 2, one of three studies that supported Gilead’s NDA filing. In his new role as SVP, inflammation, he will oversee the clinical development of the entire portfolio.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.